Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphyllin is a natural arylnaphthalide lignan extracted from several tropical plants, notably Cleistanthus collinus and Justicia gendarussa, with a history of use in traditional Chinese medicine. It is a potent and selective inhibitor of vacuolar (H^+^) ATPase (V-ATPase), interfering with endosomal acidification essential for viral entry and replication. Diphyllin exhibits broad-spectrum antiviral activity against numerous enveloped RNA and DNA viruses, including tick-borne encephalitis virus, West Nile virus, Zika virus, Rift Valley fever virus, rabies virus, herpes simplex virus type 1, and has also been tested against Ebola virus and SARS-CoV-2. In oncology, diphyllin inhibits V-ATPase in cancer cell lines, impacting mTORC1/HIF-1α/VEGF signaling and suppressing proliferation, angiogenesis, and metastasis. Diphyllin generally shows low cytotoxicity in mammalian cells at effective concentrations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphyllin.